The DOI matches its Crossref record.
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
Open accessAbstract
INTRODUCTION: Bosentan (Ro 47-0203) is a potent and mixed ETA-and ETB-receptor antagonist. Its activity has been studied in a variety of preclinical disease models. METHODS: Two double-blind placebo-controlled studies were performed to investigate the pharmacokinetics and pharmacodynamics of bosentan after single oral and intravenous doses in healthy volunteers; doses of 3, 10, 30, 100, 300, 600, 1200, and 2400 mg were given in a single ascending oral dose study, and doses of 10, 50, 250, 500, and 750 mg were given in a single ascending intravenous dose study (six subjects received active drug and two received placebo at each dose level). In an open-label crossover added to the second study, six subjects received a single oral dose of 600 mg and a single intravenous dose of 250 mg in randomized order. At regular intervals, blood pressure, pulse rate, and skin responses to intradermally injected endothelin-1 (ET-1) were recorded, and plasma levels of ET-1, proendothelin-1 (big ET-1), and ET-3, and drug and urinary levels of ET-1 and drug were determined. RESULTS: Systemic plasma clearance and volume of distribution decreased with increasing dose to limiting values of around 6 L/hr and 0.2 L/kg, respectively. The absolute bioavailability was 50% and appeared to decrease with doses above 600 mg. Plasma ET-1 increased maximally twofold (oral) and threefold (intravenous), and this increase was directly related to bosentan plasma concentrations according to an Emax model. Bosentan reversed the vasoconstrictor effect of ET-1 measured in the skin microcirculation. There was a tendency toward decreased blood pressure (approximately 5 mm Hg) and increased pulse rate (approximately 5 beats/min), neither was clearly dose dependent. Oral bosentan was well tolerated. Vomiting and local intolerability was observed at the higher intravenous doses. CONCLUSION: Bosentan is an orally bioavailable, well-tolerated, and active ET-1 antagonist with a low clearance and a moderate volume of distribution. Its intravenous use is limited because of local intolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605
Krum, H., Viskoper, R. J., Lacourciere, Y., Budde, M., & Charlon, V. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803193381202 · Cited by 570
Endothelin as a regulator of cardiovascular function in health and disease
Haynes, W. G., & Webb, D. J. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816080-00001 · Cited by 360
Barst, R. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00005-5 · Cited by 350
Metadata
- Authors
- Weber, C., Schmitt, R., Birnboeck, H., Hopfgartner, G., van Marle, S. P., Peeters, P. A. M., Jonkman, J. H. G., & Jones, C.-R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1996-08
- Volume
- 60
- Issue
- 2
- Pages
- 124-137
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2060989736
- Cited by
- 205
- References
- 0
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. https://app.cochat.ai/papers/10.1016/s0009-9236(96)90127-7
- The paper
- Weber, C., Schmitt, R., Birnboeck, H., Hopfgartner, G., van Marle, S. P., Peeters, P. A. M., Jonkman, J. H. G., & Jones, C.-R. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(96)90127-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.